Kawamura Masahumi, Inoue Yoshimasa, Oyama Takahiko, Kobayashi Koichi
Division of General Thoracic Surgery, Keio University, Tokyo, Japan.
Nihon Geka Gakkai Zasshi. 2002 Feb;103(2):229-32.
To choose the optimal chemotherapy regimens, we have employed a new chemosensitivity testing method, the collagen gel droplet embedded culture drug sensitivity test (CDDST) for patients with non-small cell lung cancer (NSCLC). This method requires fewer cancer cells(1 x 10(5) cells in 2 specimens biopsied by bronchoscopy) than conventional chemosensitivity tests and can be also used to assess cases of malignant effusion. Correlations between the in vitro and in vivo responses were: true positive ratio, 75.0% (21/28 patients); true negative ratio 85.0% (17/20 patients); and accuracy 79.2%. The median survival time (MST) of patients (n = 11) with unresectable NSCLC who were given optimal chemotherapy based on the results of the CDDST was 15.8 months and the MST of those (n = 16) who did not receive a sensitive agent was 5.6 months. There was a significant difference between these two groups (p = 0.0048, log-rank test). These results suggest that the CDDST is an effective method for chemosensitivity testing in unresectable NSCLC.
为选择最佳化疗方案，我们采用了一种新的化疗敏感性检测方法——胶原凝胶滴包埋培养药物敏感性试验（CDDST），用于非小细胞肺癌（NSCLC）患者。该方法所需癌细胞数量比传统化疗敏感性检测少（通过支气管镜活检的2个标本中为1×10⁵个细胞），且还可用于评估恶性胸腔积液病例。体外与体内反应的相关性为：真阳性率75.0%（28例患者中的21例）；真阴性率85.0%（20例患者中的17例）；准确率79.2%。根据CDDST结果接受最佳化疗的不可切除NSCLC患者（n = 11）的中位生存时间（MST）为15.8个月，未接受敏感药物治疗的患者（n = 16）的MST为5.6个月。两组之间存在显著差异（p = 0.0048，对数秩检验）。这些结果表明，CDDST是不可切除NSCLC化疗敏感性检测的有效方法。
